Interval-compressed VDC/IE
Checked 2026-09-09
Localised Ewing sarcoma, 14 alternating cycles (induction then consolidation around local therapy)
One cycle
every 28 days × 7 · about 28 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Vincristine Vinca alkaloid (microtubule inhibitor) | 2 mg/m² (maximum 2 mg) | IV | D1 | |
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 37.5 mg/m² per day (75 mg/m² per cycle; dactinomycin replaces it after 375 mg/m²) | IV | D1, 2 | |
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug) | 1,200 mg/m² with mesna | IV | D1 | |
Ifosfamide Cytotoxic chemotherapy (alkylating agent) | 1,800 mg/m² per day with mesna | IV | D15-19 | |
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative) | 100 mg/m² per day | IV | D15-19 |
Cycles
7 alternating pairs (14 cycles, each 2 weeks)
28-day cycle
Emetogenicity
High (>90%)
G-CSF
Built into the protocol
Notes
- Every-2-week cycles improved 5-year EFS from 65% to 73% versus every 3 weeks, with G-CSF after each cycle.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.